DelMar Pharmaceuticals Inc (NASDAQ:DMPI) has been assigned a consensus broker rating score of 1.50 (Buy) from the four brokers that provide coverage for the stock, Zacks Investment Research reports. One analyst has rated the stock with a hold rating and three have assigned a strong buy rating to the company.

Analysts have set a 12-month consensus target price of $9.95 for the company and are predicting that the company will post ($0.15) earnings per share for the current quarter, according to Zacks. Zacks has also given DelMar Pharmaceuticals an industry rank of 185 out of 265 based on the ratings given to its competitors.

Separately, HC Wainwright set a $12.00 target price on DelMar Pharmaceuticals and gave the company a “buy” rating in a research report on Monday, October 16th.

DelMar Pharmaceuticals (DMPI) opened at $1.46 on Monday. DelMar Pharmaceuticals has a 52-week low of $0.78 and a 52-week high of $5.39. The stock has a market capitalization of $31.54, a P/E ratio of -2.12 and a beta of 1.22.

DelMar Pharmaceuticals (NASDAQ:DMPI) last announced its earnings results on Monday, November 13th. The company reported ($0.18) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.17) by ($0.01). research analysts predict that DelMar Pharmaceuticals will post -0.54 EPS for the current year.

In other news, CEO Saiid Zarrabian purchased 60,900 shares of the company’s stock in a transaction that occurred on Tuesday, November 14th. The shares were acquired at an average cost of $0.82 per share, with a total value of $49,938.00. The transaction was disclosed in a filing with the SEC, which is available at this link.

A hedge fund recently bought a new stake in DelMar Pharmaceuticals stock. Sabby Management LLC purchased a new stake in shares of DelMar Pharmaceuticals Inc (NASDAQ:DMPI) during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor purchased 645,390 shares of the company’s stock, valued at approximately $1,484,000. Sabby Management LLC owned approximately 4.79% of DelMar Pharmaceuticals at the end of the most recent quarter. Hedge funds and other institutional investors own 17.03% of the company’s stock.

TRADEMARK VIOLATION NOTICE: “Zacks: DelMar Pharmaceuticals Inc (DMPI) Given Consensus Rating of “Buy” by Analysts” was first posted by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this article on another publication, it was illegally stolen and republished in violation of US & international trademark & copyright law. The legal version of this article can be read at https://www.thecerbatgem.com/2018/02/05/zacks-delmar-pharmaceuticals-inc-dmpi-given-consensus-rating-of-buy-by-analysts.html.

About DelMar Pharmaceuticals

DelMar Pharmaceuticals, Inc is a clinical-stage drug development company. The Company focuses on the treatment of cancer. The Company is engaged in conducting clinical trials in the United States with its product candidate, VAL-083, as a treatment for glioblastoma multiforme (GBM), a form of brain cancer.

Get a free copy of the Zacks research report on DelMar Pharmaceuticals (DMPI)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for DelMar Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DelMar Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.